As the largest series to date, we report detailed clinicopathologic data and clinical outcomes of consecutive female patients with lymph node negative, ER+/HER2- breast cancer and low RS (<18) treated at our institution and provide a comprehensive characterization of patients who developed LRR. This evidence concerns the gene ERBB2 and breast cancer.